Floatz logo

Modafinil

Narcolepsy-Cataplexy Syndrome

BioprojetSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Narcolepsy-Cataplexy Syndrome cohort.

Asset / SponsorPhaseRating
Pitolisant
Bioprojet
Phase 3BB

Same molecule, other indications

Modafinil is also rated in:

schizophreniaActive
BB
Indicative · Phase 4
66 / 100
View asset →
schizoaffective disorderActive
BB
Indicative · Phase 4
65 / 100
View asset →
sleep disorderActive
BB
Indicative · Phase 3
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →